JP6774562B2 - 置換ピロリジン化合物およびその使用 - Google Patents
置換ピロリジン化合物およびその使用 Download PDFInfo
- Publication number
- JP6774562B2 JP6774562B2 JP2019510869A JP2019510869A JP6774562B2 JP 6774562 B2 JP6774562 B2 JP 6774562B2 JP 2019510869 A JP2019510869 A JP 2019510869A JP 2019510869 A JP2019510869 A JP 2019510869A JP 6774562 B2 JP6774562 B2 JP 6774562B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- alkyl
- inhibitors
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c1c(C(N*)=O)[n](CCCCCCC2)c2c1C(C(N*)=O)=O Chemical compound *c1c(C(N*)=O)[n](CCCCCCC2)c2c1C(C(N*)=O)=O 0.000 description 6
- BOOOFYIGDHEYMP-HXUWFJFHSA-N C[C@](C(F)(F)F)(C(N)=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2)cc(F)c2F)=O)c1C)=O)=O Chemical compound C[C@](C(F)(F)F)(C(N)=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2)cc(F)c2F)=O)c1C)=O)=O BOOOFYIGDHEYMP-HXUWFJFHSA-N 0.000 description 2
- KYQJFMXGDILKQG-UHFFFAOYSA-N Cc1c(C(Nc(ccnc2C(F)F)c2F)=O)[n](CCC2)c2c1C(C(NC(C1)(CC1(F)F)C(NC)=O)=O)=O Chemical compound Cc1c(C(Nc(ccnc2C(F)F)c2F)=O)[n](CCC2)c2c1C(C(NC(C1)(CC1(F)F)C(NC)=O)=O)=O KYQJFMXGDILKQG-UHFFFAOYSA-N 0.000 description 2
- HXJQSAQAQAPTAI-UHFFFAOYSA-N Cc1c(C(Nc2cc(C(F)F)ncc2)=O)[n](CCC2)c2c1C(C(NC(C1)(CC1(F)F)c1c[nH]nn1)=O)=O Chemical compound Cc1c(C(Nc2cc(C(F)F)ncc2)=O)[n](CCC2)c2c1C(C(NC(C1)(CC1(F)F)c1c[nH]nn1)=O)=O HXJQSAQAQAPTAI-UHFFFAOYSA-N 0.000 description 2
- ISBDYYOLPRINPR-UHFFFAOYSA-N CC(C)(C(NC)=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2)cc(C(F)F)c2F)=O)c1C)=O)=O Chemical compound CC(C)(C(NC)=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2)cc(C(F)F)c2F)=O)c1C)=O)=O ISBDYYOLPRINPR-UHFFFAOYSA-N 0.000 description 1
- JDCAEUCJNXMESQ-UHFFFAOYSA-N CC(C)(C(NC)=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2Cl)ccc2F)=O)c1C)=O)=O Chemical compound CC(C)(C(NC)=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2Cl)ccc2F)=O)c1C)=O)=O JDCAEUCJNXMESQ-UHFFFAOYSA-N 0.000 description 1
- AKFLHODMFPIXAH-UHFFFAOYSA-N CC(C)(C)OC(NC1(CC1)c1c[nH]nn1)=O Chemical compound CC(C)(C)OC(NC1(CC1)c1c[nH]nn1)=O AKFLHODMFPIXAH-UHFFFAOYSA-N 0.000 description 1
- WYKVCZXBXSNIQV-UHFFFAOYSA-N CC(C)C1(COC1)C(N)(N)N Chemical compound CC(C)C1(COC1)C(N)(N)N WYKVCZXBXSNIQV-UHFFFAOYSA-N 0.000 description 1
- HIXLPXCVOTTYCF-UHFFFAOYSA-N CC(C1)(CS1=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2F)ccc2F)=O)c1C)=O)=O Chemical compound CC(C1)(CS1=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2F)ccc2F)=O)c1C)=O)=O HIXLPXCVOTTYCF-UHFFFAOYSA-N 0.000 description 1
- GJHZZRVGCDRGBR-UHFFFAOYSA-N CCC(C(CCF)(CCF)NC(OCc1ccccc1)=O)=O Chemical compound CCC(C(CCF)(CCF)NC(OCc1ccccc1)=O)=O GJHZZRVGCDRGBR-UHFFFAOYSA-N 0.000 description 1
- GXWYXULRLAFDFE-UHFFFAOYSA-N CCOC(C(c1c(CCC2)[n]2c(C(OC)=O)c1C)=O)=O Chemical compound CCOC(C(c1c(CCC2)[n]2c(C(OC)=O)c1C)=O)=O GXWYXULRLAFDFE-UHFFFAOYSA-N 0.000 description 1
- BOOOFYIGDHEYMP-FQEVSTJZSA-N C[C@@](C(F)(F)F)(C(N)=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2F)ccc2F)=O)c1C)=O)=O Chemical compound C[C@@](C(F)(F)F)(C(N)=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2F)ccc2F)=O)c1C)=O)=O BOOOFYIGDHEYMP-FQEVSTJZSA-N 0.000 description 1
- GFFVOEVMSGLFDI-NRFANRHFSA-N C[C@@](C(F)(F)F)(C(NC)=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2)cc(F)c2F)=O)c1C)=O)=O Chemical compound C[C@@](C(F)(F)F)(C(NC)=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2)cc(F)c2F)=O)c1C)=O)=O GFFVOEVMSGLFDI-NRFANRHFSA-N 0.000 description 1
- GFFVOEVMSGLFDI-OAQYLSRUSA-N C[C@](C(F)(F)F)(C(NC)=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2)cc(F)c2F)=O)c1C)=O)=O Chemical compound C[C@](C(F)(F)F)(C(NC)=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2)cc(F)c2F)=O)c1C)=O)=O GFFVOEVMSGLFDI-OAQYLSRUSA-N 0.000 description 1
- HIXLPXCVOTTYCF-NEWFWRPPSA-N C[C@](C1)(C[S@@]1=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2)cc(F)c2F)=O)c1C)=O)=O Chemical compound C[C@](C1)(C[S@@]1=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2)cc(F)c2F)=O)c1C)=O)=O HIXLPXCVOTTYCF-NEWFWRPPSA-N 0.000 description 1
- HIXLPXCVOTTYCF-JUKHWHIISA-N C[C@](C1)(C[S@]1=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2F)ccc2F)=O)c1C)=O)=O Chemical compound C[C@](C1)(C[S@]1=O)NC(C(c1c(CCC2)[n]2c(C(Nc(cc2F)ccc2F)=O)c1C)=O)=O HIXLPXCVOTTYCF-JUKHWHIISA-N 0.000 description 1
- KGRFDNOJYUWCRH-UHFFFAOYSA-N Cc1c(C(Nc(cc2)cc(C#N)c2F)=O)[n](C(C2)C2C2)c2c1C(C(NC1(CC1)c1nnc[s]1)=O)=O Chemical compound Cc1c(C(Nc(cc2)cc(C#N)c2F)=O)[n](C(C2)C2C2)c2c1C(C(NC1(CC1)c1nnc[s]1)=O)=O KGRFDNOJYUWCRH-UHFFFAOYSA-N 0.000 description 1
- ZMZJBUWFGAOAHT-UHFFFAOYSA-N Cc1c(C(Nc(cc2)cc(Cl)c2F)=O)[n](C(C2)C2C2)c2c1C(C(NC1(CC1)C(SC=N)=N)=O)=O Chemical compound Cc1c(C(Nc(cc2)cc(Cl)c2F)=O)[n](C(C2)C2C2)c2c1C(C(NC1(CC1)C(SC=N)=N)=O)=O ZMZJBUWFGAOAHT-UHFFFAOYSA-N 0.000 description 1
- AMRLYSSGANCGGU-UHFFFAOYSA-N Cc1c(C(Nc(cc2)cc(Cl)c2F)=O)[n](CCC2)c2c1C(C(NC(C1)(CC1(F)F)C#C)=O)=O Chemical compound Cc1c(C(Nc(cc2)cc(Cl)c2F)=O)[n](CCC2)c2c1C(C(NC(C1)(CC1(F)F)C#C)=O)=O AMRLYSSGANCGGU-UHFFFAOYSA-N 0.000 description 1
- NNIPCTNJBVAMCQ-BOPFTXTBSA-N Cc1c(C(Nc(cc2)cc(Cl)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)/C(/N)=C/N(C)N)=O)=O Chemical compound Cc1c(C(Nc(cc2)cc(Cl)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)/C(/N)=C/N(C)N)=O)=O NNIPCTNJBVAMCQ-BOPFTXTBSA-N 0.000 description 1
- LRUHUPVDHZBOIV-UHFFFAOYSA-N Cc1c(C(Nc(cc2)cc(Cl)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)c1ccccc1)=O)=O Chemical compound Cc1c(C(Nc(cc2)cc(Cl)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)c1ccccc1)=O)=O LRUHUPVDHZBOIV-UHFFFAOYSA-N 0.000 description 1
- FKUYEFIBLJWFHG-UHFFFAOYSA-N Cc1c(C(Nc(cc2)cc(Cl)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)c1nnc(C)[o]1)=O)=O Chemical compound Cc1c(C(Nc(cc2)cc(Cl)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)c1nnc(C)[o]1)=O)=O FKUYEFIBLJWFHG-UHFFFAOYSA-N 0.000 description 1
- JHZWOBJZFZOGNA-UHFFFAOYSA-O Cc1c(C(Nc(cc2)cc(F)c2F)=O)[n](C(C2)C2C2)c2c1C(C(NC1(CC1)C(SC=[NH2+])=N)=O)=O Chemical compound Cc1c(C(Nc(cc2)cc(F)c2F)=O)[n](C(C2)C2C2)c2c1C(C(NC1(CC1)C(SC=[NH2+])=N)=O)=O JHZWOBJZFZOGNA-UHFFFAOYSA-O 0.000 description 1
- HOLWVMYHUMMPKG-UHFFFAOYSA-N Cc1c(C(Nc(cc2)cc(F)c2F)=O)[n](CCC2)c2c1C(C(NC(C1)(C2)CC12C#N)=O)=O Chemical compound Cc1c(C(Nc(cc2)cc(F)c2F)=O)[n](CCC2)c2c1C(C(NC(C1)(C2)CC12C#N)=O)=O HOLWVMYHUMMPKG-UHFFFAOYSA-N 0.000 description 1
- RSYSXPQRXLXDQX-UHFFFAOYSA-N Cc1c(C(Nc(cc2)cc(F)c2F)=O)[n](CCC2)c2c1C(C(NC(C1)(CC1(F)F)C(NC)=O)=O)=O Chemical compound Cc1c(C(Nc(cc2)cc(F)c2F)=O)[n](CCC2)c2c1C(C(NC(C1)(CC1(F)F)C(NC)=O)=O)=O RSYSXPQRXLXDQX-UHFFFAOYSA-N 0.000 description 1
- RCFHZLKULPMUMS-WPZCJLIBSA-N Cc1c(C(Nc(cc2)ccc2F)=O)[n]([C@H](C2)C2C2)c2c1C(C(NC(C1)(CC1(F)F)c1cnn[nH]1)=O)=O Chemical compound Cc1c(C(Nc(cc2)ccc2F)=O)[n]([C@H](C2)C2C2)c2c1C(C(NC(C1)(CC1(F)F)c1cnn[nH]1)=O)=O RCFHZLKULPMUMS-WPZCJLIBSA-N 0.000 description 1
- GARXGXIMSVEZHA-IUODEOHRSA-N Cc1c(C(Nc(cc2)ccc2F)=O)[n]([C@H](C2)[C@H]2C2)c2c1C(C(NC(C1)(CC1(F)F)C(NC)=O)=O)=O Chemical compound Cc1c(C(Nc(cc2)ccc2F)=O)[n]([C@H](C2)[C@H]2C2)c2c1C(C(NC(C1)(CC1(F)F)C(NC)=O)=O)=O GARXGXIMSVEZHA-IUODEOHRSA-N 0.000 description 1
- HNQOBZHSSXFFIS-IUODEOHRSA-N Cc1c(C(Nc(cc2)ccc2F)=O)[n]([C@H](C2)[C@H]2C2)c2c1C(C(NC1(CC1)c1cnn[nH]1)=O)=O Chemical compound Cc1c(C(Nc(cc2)ccc2F)=O)[n]([C@H](C2)[C@H]2C2)c2c1C(C(NC1(CC1)c1cnn[nH]1)=O)=O HNQOBZHSSXFFIS-IUODEOHRSA-N 0.000 description 1
- ARYFPUZRBRDBJD-UHFFFAOYSA-N Cc1c(C(Nc(cc2Cl)ccc2F)=O)[n](CCC2)c2c1C(C(NC(C1)(C2)CC12C(N)=O)=O)=O Chemical compound Cc1c(C(Nc(cc2Cl)ccc2F)=O)[n](CCC2)c2c1C(C(NC(C1)(C2)CC12C(N)=O)=O)=O ARYFPUZRBRDBJD-UHFFFAOYSA-N 0.000 description 1
- VODUOCVTPPLDOX-UHFFFAOYSA-N Cc1c(C(Nc(cc2Cl)ccc2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)C(NC)=O)=O)=O Chemical compound Cc1c(C(Nc(cc2Cl)ccc2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)C(NC)=O)=O)=O VODUOCVTPPLDOX-UHFFFAOYSA-N 0.000 description 1
- YWVFDVWCGWUNEE-UHFFFAOYSA-N Cc1c(C(Nc(cc2Cl)ccc2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)c1nnc(C)[nH]1)=O)=O Chemical compound Cc1c(C(Nc(cc2Cl)ccc2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)c1nnc(C)[nH]1)=O)=O YWVFDVWCGWUNEE-UHFFFAOYSA-N 0.000 description 1
- VBOBNVOCPFMYPA-IAQYHMDHSA-N Cc1c(C(Nc(cc2Cl)ccc2F)=O)[n]([C@H](C2)[C@H]2C2)c2c1C(C(NC1(CC1)c1c[nH]nn1)=O)=O Chemical compound Cc1c(C(Nc(cc2Cl)ccc2F)=O)[n]([C@H](C2)[C@H]2C2)c2c1C(C(NC1(CC1)c1c[nH]nn1)=O)=O VBOBNVOCPFMYPA-IAQYHMDHSA-N 0.000 description 1
- SLPYPUIPQODCTG-UHFFFAOYSA-N Cc1c(C(Nc(cc2F)cc(F)c2F)=O)[n](C(C2)C2C2)c2c1C(C(NC1(CC1)C(SC=N)=N)=O)=O Chemical compound Cc1c(C(Nc(cc2F)cc(F)c2F)=O)[n](C(C2)C2C2)c2c1C(C(NC1(CC1)C(SC=N)=N)=O)=O SLPYPUIPQODCTG-UHFFFAOYSA-N 0.000 description 1
- NQNSGOIFUIMYBZ-UHFFFAOYSA-O Cc1c(C(Nc(cc2F)cc(F)c2F)=O)[n](C(C2)C2C2)c2c1C(C(NC1(CC1)C1=[N+]=CS1)=O)=O Chemical compound Cc1c(C(Nc(cc2F)cc(F)c2F)=O)[n](C(C2)C2C2)c2c1C(C(NC1(CC1)C1=[N+]=CS1)=O)=O NQNSGOIFUIMYBZ-UHFFFAOYSA-O 0.000 description 1
- WRMTULCTQIDTJD-UHFFFAOYSA-N Cc1c(C(Nc(cc2F)cc(F)c2F)=O)[n](CCC2)c2c1C(C(NC(C1)(CC1(F)F)C(N)=O)=O)=O Chemical compound Cc1c(C(Nc(cc2F)cc(F)c2F)=O)[n](CCC2)c2c1C(C(NC(C1)(CC1(F)F)C(N)=O)=O)=O WRMTULCTQIDTJD-UHFFFAOYSA-N 0.000 description 1
- JSRZDJNDLPMVHE-UHFFFAOYSA-N Cc1c(C(Nc(cc2F)cc(F)c2F)=O)[n](CCC2)c2c1C(C(NC(C1)(CC1(F)F)c1c[nH]nn1)=O)=O Chemical compound Cc1c(C(Nc(cc2F)cc(F)c2F)=O)[n](CCC2)c2c1C(C(NC(C1)(CC1(F)F)c1c[nH]nn1)=O)=O JSRZDJNDLPMVHE-UHFFFAOYSA-N 0.000 description 1
- JQWCEYRILZTJJD-UHFFFAOYSA-N Cc1c(C(Nc(cc2F)cc(F)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)c1ccccc1)=O)=O Chemical compound Cc1c(C(Nc(cc2F)cc(F)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)c1ccccc1)=O)=O JQWCEYRILZTJJD-UHFFFAOYSA-N 0.000 description 1
- NYRULGHTEHZRQN-UHFFFAOYSA-N Cc1c(C(Nc(cc2F)cc(F)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)c1nnc(C)[o]1)=O)=O Chemical compound Cc1c(C(Nc(cc2F)cc(F)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)c1nnc(C)[o]1)=O)=O NYRULGHTEHZRQN-UHFFFAOYSA-N 0.000 description 1
- QWRDHKUPHMFQQN-IAQYHMDHSA-N Cc1c(C(Nc(cc2F)ccc2F)=O)[n]([C@H](C2)[C@H]2C2)c2c1C(C(NC(C1)(CC1(F)F)C(NC)=O)=O)=O Chemical compound Cc1c(C(Nc(cc2F)ccc2F)=O)[n]([C@H](C2)[C@H]2C2)c2c1C(C(NC(C1)(CC1(F)F)C(NC)=O)=O)=O QWRDHKUPHMFQQN-IAQYHMDHSA-N 0.000 description 1
- GMQLGJJXMDVYBI-UHFFFAOYSA-O Cc1c(C(Nc(ccc(F)c2F)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)C([NH3+])=CN[NH2+2])=O)=O Chemical compound Cc1c(C(Nc(ccc(F)c2F)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)C([NH3+])=CN[NH2+2])=O)=O GMQLGJJXMDVYBI-UHFFFAOYSA-O 0.000 description 1
- QMHZTQOYPKXGJC-UHFFFAOYSA-N Cc1c(C(Nc(ccc(F)c2F)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)c1c[nH]nn1)=O)=O Chemical compound Cc1c(C(Nc(ccc(F)c2F)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)c1c[nH]nn1)=O)=O QMHZTQOYPKXGJC-UHFFFAOYSA-N 0.000 description 1
- LXETZQNHIIREER-GDNBJRDFSA-N Cc1c(C(Nc(cccc2Cl)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)/C(/N)=C/NN)=O)=O Chemical compound Cc1c(C(Nc(cccc2Cl)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)/C(/N)=C/NN)=O)=O LXETZQNHIIREER-GDNBJRDFSA-N 0.000 description 1
- YPSAWSLQXCVOFK-UHFFFAOYSA-O Cc1c(C(Nc(cccc2Cl)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)C(NN)=C[NH3+])=O)=O Chemical compound Cc1c(C(Nc(cccc2Cl)c2F)=O)[n](CCC2)c2c1C(C(NC1(CC1)C(NN)=C[NH3+])=O)=O YPSAWSLQXCVOFK-UHFFFAOYSA-O 0.000 description 1
- BTBUESRCBXWRFW-UHFFFAOYSA-N Cc1c(C(Nc(ccnc2C(F)F)c2F)=O)[n](C(C2)C2C2)c2c1C(C(NC1(CC1)c1nnc[s]1)=O)=O Chemical compound Cc1c(C(Nc(ccnc2C(F)F)c2F)=O)[n](C(C2)C2C2)c2c1C(C(NC1(CC1)c1nnc[s]1)=O)=O BTBUESRCBXWRFW-UHFFFAOYSA-N 0.000 description 1
- ZTETUIHLYHMGBX-UHFFFAOYSA-N Cc1c(C(Nc(ccnc2C(F)F)c2F)=O)[n](CCC2)c2c1C(C(NC(C1)(CC1(F)F)c1c[nH]nn1)=O)=O Chemical compound Cc1c(C(Nc(ccnc2C(F)F)c2F)=O)[n](CCC2)c2c1C(C(NC(C1)(CC1(F)F)c1c[nH]nn1)=O)=O ZTETUIHLYHMGBX-UHFFFAOYSA-N 0.000 description 1
- ACXVSWWSVCRTBR-SECBINFHSA-N Cc1c(C(Nc(ccnc2C(F)F)c2F)=O)[n](C[C@@H](C2)F)c2c1C(C(NC1(COC1)C(F)(F)F)=O)=O Chemical compound Cc1c(C(Nc(ccnc2C(F)F)c2F)=O)[n](C[C@@H](C2)F)c2c1C(C(NC1(COC1)C(F)(F)F)=O)=O ACXVSWWSVCRTBR-SECBINFHSA-N 0.000 description 1
- UFNFDIKXQQEPRA-UHFFFAOYSA-N Cc1c(C(Nc2cc(C#N)ccc2)=O)[n](CCC2)c2c1C(C(NC1(CC1)C1=CNNN1)=O)=O Chemical compound Cc1c(C(Nc2cc(C#N)ccc2)=O)[n](CCC2)c2c1C(C(NC1(CC1)C1=CNNN1)=O)=O UFNFDIKXQQEPRA-UHFFFAOYSA-N 0.000 description 1
- MVCRBBSVTDUREK-UHFFFAOYSA-N Cc1c(C(Nc2cc(C(F)F)ccc2)=O)[n](CCC2)c2c1C(C(NC(C1)(CC1(F)F)C(NC)=O)=O)=O Chemical compound Cc1c(C(Nc2cc(C(F)F)ccc2)=O)[n](CCC2)c2c1C(C(NC(C1)(CC1(F)F)C(NC)=O)=O)=O MVCRBBSVTDUREK-UHFFFAOYSA-N 0.000 description 1
- MADCJRUEHZZXGR-UHFFFAOYSA-N Cc1c(C(Nc2cc(C(F)F)ccc2)=O)[n](CCC2)c2c1C(C(NC1(CC1)c1c[nH]nn1)=O)=O Chemical compound Cc1c(C(Nc2cc(C(F)F)ccc2)=O)[n](CCC2)c2c1C(C(NC1(CC1)c1c[nH]nn1)=O)=O MADCJRUEHZZXGR-UHFFFAOYSA-N 0.000 description 1
- XZYJIPIVMNKWNI-UHFFFAOYSA-N Cc1c(C(Nc2cc(C(F)F)ncc2)=O)[n](C(C2)C2C2)c2c1C(C(NC1(CC1)c1nnc[s]1)=O)=O Chemical compound Cc1c(C(Nc2cc(C(F)F)ncc2)=O)[n](C(C2)C2C2)c2c1C(C(NC1(CC1)c1nnc[s]1)=O)=O XZYJIPIVMNKWNI-UHFFFAOYSA-N 0.000 description 1
- SCPXCDRTCXNZCL-UHFFFAOYSA-N Cc1c(C(Nc2cc(Cl)cc(Cl)c2)=O)[n](CCC2)c2c1C(C(NC1(CC1)c1c[nH]nn1)=O)=O Chemical compound Cc1c(C(Nc2cc(Cl)cc(Cl)c2)=O)[n](CCC2)c2c1C(C(NC1(CC1)c1c[nH]nn1)=O)=O SCPXCDRTCXNZCL-UHFFFAOYSA-N 0.000 description 1
- HQTZBWCPEHWQPZ-UHFFFAOYSA-N Cc1c(C(Nc2cc(F)cc(Cl)c2)=O)[n](CCC2)c2c1C(C(NC1(CC1)C1=CNNN1)=O)=O Chemical compound Cc1c(C(Nc2cc(F)cc(Cl)c2)=O)[n](CCC2)c2c1C(C(NC1(CC1)C1=CNNN1)=O)=O HQTZBWCPEHWQPZ-UHFFFAOYSA-N 0.000 description 1
- XDLVLSYVZBRROH-UHFFFAOYSA-N Cc1c(C(Nc2cc(F)ccc2)=O)[n](CCC2)c2c1C(C(NC1(CC1)C#C)=O)=O Chemical compound Cc1c(C(Nc2cc(F)ccc2)=O)[n](CCC2)c2c1C(C(NC1(CC1)C#C)=O)=O XDLVLSYVZBRROH-UHFFFAOYSA-N 0.000 description 1
- XQDKBKGJSNEZTF-UHFFFAOYSA-O Cc1c(C(Nc2cccc(F)c2)=O)[n](CCC2)c2c1C(C(NC1(CC1)C(NC)=CN[NH3+])=O)=O Chemical compound Cc1c(C(Nc2cccc(F)c2)=O)[n](CCC2)c2c1C(C(NC1(CC1)C(NC)=CN[NH3+])=O)=O XQDKBKGJSNEZTF-UHFFFAOYSA-O 0.000 description 1
- CMPCXXBMUXKBFA-IUODEOHRSA-N Cc1c(C(Nc2ccnc(C(F)F)c2)=O)[n]([C@H](C2)[C@H]2C2)c2c1C(C(NC1(CC1)C1=CNN(C)N1)=O)=O Chemical compound Cc1c(C(Nc2ccnc(C(F)F)c2)=O)[n]([C@H](C2)[C@H]2C2)c2c1C(C(NC1(CC1)C1=CNN(C)N1)=O)=O CMPCXXBMUXKBFA-IUODEOHRSA-N 0.000 description 1
- OQBSLJGLWRTTND-ZYHUDNBSSA-N Cc1c(C(Nc2ccnc(C(F)F)c2F)=O)[n]([C@H](C2)[C@H]2C2)c2c1C(C(NC1(CC1)c1c[nH]nn1)=O)=O Chemical compound Cc1c(C(Nc2ccnc(C(F)F)c2F)=O)[n]([C@H](C2)[C@H]2C2)c2c1C(C(NC1(CC1)c1c[nH]nn1)=O)=O OQBSLJGLWRTTND-ZYHUDNBSSA-N 0.000 description 1
- QWJBPWJXMJVPDN-UHFFFAOYSA-N Cc1c(C(O)=O)[n](CCC2)c2c1C(C(O)=O)=O Chemical compound Cc1c(C(O)=O)[n](CCC2)c2c1C(C(O)=O)=O QWJBPWJXMJVPDN-UHFFFAOYSA-N 0.000 description 1
- HGGSDAHVIQBNFG-UHFFFAOYSA-N Cc1c(C(O[n]2nnc3c2nccc3)=O)[n](CCC2)c2c1C(C(NC1(CC1)C#C)=O)=O Chemical compound Cc1c(C(O[n]2nnc3c2nccc3)=O)[n](CCC2)c2c1C(C(NC1(CC1)C#C)=O)=O HGGSDAHVIQBNFG-UHFFFAOYSA-N 0.000 description 1
- KSCVQJSNYDFHOT-UHFFFAOYSA-N NC(C1)(CC1(F)F)C(O)=O Chemical compound NC(C1)(CC1(F)F)C(O)=O KSCVQJSNYDFHOT-UHFFFAOYSA-N 0.000 description 1
- NYYPFTITHJCRHQ-UHFFFAOYSA-N NC1(CC1)C1=CNCN1 Chemical compound NC1(CC1)C1=CNCN1 NYYPFTITHJCRHQ-UHFFFAOYSA-N 0.000 description 1
- SEONRICTAYAILT-UHFFFAOYSA-N OC(C(C1)(CC1(F)F)NC(OCc1ccccc1)=O)=O Chemical compound OC(C(C1)(CC1(F)F)NC(OCc1ccccc1)=O)=O SEONRICTAYAILT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020167860A JP6983296B2 (ja) | 2016-08-26 | 2020-10-02 | 置換ピロリジン化合物およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380063P | 2016-08-26 | 2016-08-26 | |
| US62/380,063 | 2016-08-26 | ||
| US201662416020P | 2016-11-01 | 2016-11-01 | |
| US62/416,020 | 2016-11-01 | ||
| PCT/US2017/048565 WO2018039531A1 (en) | 2016-08-26 | 2017-08-25 | Substituted pyrrolizine compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020167860A Division JP6983296B2 (ja) | 2016-08-26 | 2020-10-02 | 置換ピロリジン化合物およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019530652A JP2019530652A (ja) | 2019-10-24 |
| JP6774562B2 true JP6774562B2 (ja) | 2020-10-28 |
Family
ID=59772819
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510869A Active JP6774562B2 (ja) | 2016-08-26 | 2017-08-25 | 置換ピロリジン化合物およびその使用 |
| JP2020167860A Active JP6983296B2 (ja) | 2016-08-26 | 2020-10-02 | 置換ピロリジン化合物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020167860A Active JP6983296B2 (ja) | 2016-08-26 | 2020-10-02 | 置換ピロリジン化合物およびその使用 |
Country Status (31)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102396753B1 (ko) | 2014-06-11 | 2022-05-12 | 베나토알엑스 파마슈티컬스, 인크. | 베타-락타마제 억제제 |
| JOP20190024A1 (ar) * | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| MX2020004838A (es) | 2017-11-02 | 2020-10-16 | Aicuris Gmbh & Co Kg | Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb). |
| EA202091113A1 (ru) | 2017-11-02 | 2020-08-28 | Айкурис Гмбх Унд Ко. Кг | Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv) |
| US11247965B2 (en) | 2017-12-11 | 2022-02-15 | VenatoRx Pharmaceuticals, Inc. | Hepatitis B capsid assembly modulators |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ, インコーポレイテッド | Hbv複製阻害剤としての置換ピロリジン化合物 |
| WO2019185016A1 (zh) | 2018-03-30 | 2019-10-03 | 正大天晴药业集团股份有限公司 | 含有n杂五元环的衣壳蛋白装配抑制剂、其药物组合物和用途 |
| CN110437232B (zh) * | 2018-05-04 | 2022-04-12 | 上海长森药业有限公司 | 双并环脲类核衣壳抑制剂及其药物用途 |
| SG11202011685QA (en) * | 2018-05-25 | 2020-12-30 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof |
| WO2019241292A1 (en) * | 2018-06-11 | 2019-12-19 | VenatoRx Pharmaceuticals, Inc. | Hepatitis b capsid assembly modulators |
| TWI869058B (zh) * | 2018-07-27 | 2025-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代四氫環戊[c]吡咯、經取代二氫吡咯,其類似物及使用其之方法 |
| IL328538A (en) * | 2018-10-05 | 2026-07-01 | Univ Emory | Monomeric and multimeric hepatitis B antivirals |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US12091405B2 (en) | 2018-11-01 | 2024-09-17 | Merck Sharp & Dohme Llc | Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors |
| AR117188A1 (es) | 2018-11-02 | 2021-07-21 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
| AR116947A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| UY38434A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
| PY1991606A (es) | 2018-11-02 | 2022-02-10 | Aicuris Gmbh & Co Kg | Nueva urea 6,7-dihidro-4h-pirazolo [4,3-c] piridinas activas contra el virus de la hepatitis b (vhb) |
| US20220009945A1 (en) | 2018-11-02 | 2022-01-13 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-thiazole[5,4-c]pyridines active against the hepatitis b virus (hbv) |
| EA202092159A1 (ru) * | 2019-01-25 | 2020-12-15 | Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. | Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение |
| CN113365999B (zh) * | 2019-01-31 | 2023-04-14 | 正大天晴药业集团股份有限公司 | 含有吡咯并杂环的衣壳蛋白装配抑制剂 |
| AU2020223865A1 (en) | 2019-02-22 | 2021-07-15 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| IL286902B2 (en) * | 2019-04-03 | 2025-03-01 | Aligos Therapeutics Inc | Pyrrole compounds |
| EP3962909B1 (en) * | 2019-04-30 | 2023-10-04 | AiCuris GmbH & Co. KG | Novel oxalyl piperazines active against the hepatitis b virus (hbv) |
| MX2021013086A (es) | 2019-04-30 | 2021-11-17 | Aicuris Gmbh & Co Kg | Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb). |
| US20220306647A1 (en) | 2019-04-30 | 2022-09-29 | Aicuris Gmbh & Co. Kg | Novel indole-2-carboxamides active against the hepatitus b virus (hbv) |
| KR20220002498A (ko) | 2019-04-30 | 2022-01-06 | 아이쿠리스 게엠베하 운트 코. 카게 | B형 간염 바이러스 (hbv)에 대해 활성인 신규 인돌리진-2-카르복스아미드 |
| WO2020255013A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives |
| US12378192B2 (en) | 2019-09-29 | 2025-08-05 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystalline form of capsid protein assembly inhibitor containing N hetero five-membered ring, and application thereof |
| WO2021058001A1 (zh) * | 2019-09-29 | 2021-04-01 | 正大天晴药业集团股份有限公司 | N杂五元环化合物的晶型及其应用 |
| HRP20241379T1 (hr) | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | Cjepiva za hbv i postupci za liječenje hbv |
| EP4245372A3 (en) | 2019-11-13 | 2023-11-22 | Xi'An Xintong Pharmaceutical Research Co., Ltd. | Hbv inhibitor and use thereof |
| EP4063366A4 (en) * | 2019-11-22 | 2023-12-20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | CRYSTAL FORM OF NUCLEOPROTEIN INHIBITOR AND USE THEREOF |
| KR102987126B1 (ko) | 2020-03-20 | 2026-07-07 | 길리애드 사이언시즈, 인코포레이티드 | 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법 |
| WO2021197486A1 (zh) * | 2020-04-03 | 2021-10-07 | 东莞市东阳光新药研发有限公司 | 新型螺环类化合物及其在药物中的应用 |
| EP4241770A1 (en) * | 2020-11-05 | 2023-09-13 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pharmaceutical combination containing capsid protein inhibitor and nucleoside analog |
| WO2022143610A1 (zh) * | 2020-12-29 | 2022-07-07 | 广东东阳光药业有限公司 | 新型酰胺吡咯类化合物及其在药物中的应用 |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| TW202608468A (zh) | 2024-05-13 | 2026-03-01 | 美商基利科學股份有限公司 | 組合療法 |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (249)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1032805A (en) | 1903-03-11 | 1912-07-16 | Miller O A Treeing Machine Co | Shoe-form. |
| US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
| MX9200299A (es) | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
| CA2258728C (en) | 1996-06-19 | 2011-09-27 | Rhone Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| US5733912A (en) | 1997-02-19 | 1998-03-31 | Abbott Laboratories | 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission |
| EP1027042A4 (en) | 1997-09-29 | 2004-08-18 | Bristol Myers Squibb Co | FARNESYL PROTEIN TRANSFERASE INHIBITORS |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| AU4231299A (en) | 1998-06-04 | 1999-12-20 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| HK1045306A1 (zh) | 1999-06-03 | 2002-11-22 | Abbott Laboratories | 抑制细胞黏附的抗炎化合物 |
| AU6076000A (en) | 1999-07-30 | 2001-02-19 | Vertex Pharmaceuticals Incorporated | Cyclic amine derivatives for the treatment of neurological diseases |
| WO2001014336A1 (en) | 1999-08-20 | 2001-03-01 | Nippon Kayaku Kabushiki Kaisha | Benzene derivatives substituted by aromatic ring and process for producing the same |
| WO2001098301A1 (en) | 2000-06-20 | 2001-12-27 | Japan Tobacco Inc. | Pyrazolopyridine compounds and use thereof as drugs |
| GB0021885D0 (en) | 2000-09-06 | 2000-10-18 | Fujisawa Pharmaceutical Co | New use |
| DE10046029A1 (de) | 2000-09-18 | 2002-03-28 | Bayer Ag | Indazole |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| NZ526883A (en) | 2001-02-20 | 2005-11-25 | Chugai Pharmaceutical Co Ltd | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| JP4176477B2 (ja) | 2001-03-01 | 2008-11-05 | 塩野義製薬株式会社 | Hivインテグラーゼ阻害活性を有する含窒素芳香族複素環誘導体 |
| MXPA03009000A (es) | 2001-04-13 | 2004-02-12 | Boehringer Ingelheim Pharma | Compuestos benzo-fusionados 1,4-disustituidos. |
| ATE445400T1 (de) | 2001-05-25 | 2009-10-15 | Bristol Myers Squibb Co | Hydantion-derivate als hemmer von matrix- metalloproteinasen |
| WO2003007888A2 (en) | 2001-07-20 | 2003-01-30 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
| US7294624B2 (en) | 2001-12-20 | 2007-11-13 | Bristol Myers Squibb Company | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases |
| US20030236277A1 (en) * | 2002-02-14 | 2003-12-25 | Kadow John F. | Indole, azaindole and related heterocyclic pyrrolidine derivatives |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| RU2368600C2 (ru) | 2002-04-25 | 2009-09-27 | Оно Фармасьютикл Ко., Лтд. | Производные дикетогидразина, фармацевтическая композиция, содержащая такие производные в качестве активного ингредиента, и их применение |
| WO2004024705A1 (ja) | 2002-09-10 | 2004-03-25 | Takeda Pharmaceutical Company Limited | 5員複素環化合物 |
| WO2004024727A2 (en) | 2002-09-13 | 2004-03-25 | Synta Pharmaceuticals Corp. | Synthesis of indolizines |
| JPWO2004026873A1 (ja) | 2002-09-18 | 2006-01-19 | 小野薬品工業株式会社 | トリアザスピロ[5.5]ウンデカン誘導体およびそれらを有効成分とする薬剤 |
| AU2002354054A1 (en) | 2002-10-18 | 2004-05-04 | Ono Pharmaceutical Co., Ltd. | Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
| WO2004050613A2 (en) | 2002-12-02 | 2004-06-17 | Gilead Sciences, Inc. | 2-substituted-3-propenamide derivatives and methods of using the same |
| US7320989B2 (en) | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
| JP2006520385A (ja) | 2003-03-13 | 2006-09-07 | シンタ ファーマスーティカルズ コーポレイション | 縮合ピロール化合物 |
| EP1479676A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Benzimidazole-derivatives as factor xa inhibitors |
| SG146624A1 (en) | 2003-09-11 | 2008-10-30 | Kemia Inc | Cytokine inhibitors |
| WO2005033072A2 (en) | 2003-09-30 | 2005-04-14 | Scios Inc. | Heterocyclic amides and sulfonamides |
| EP1678146A1 (en) | 2003-10-23 | 2006-07-12 | Pharmacia Corporation | Pyrimidine compounds for the treatment of inflammation |
| US7816353B2 (en) | 2003-10-24 | 2010-10-19 | Exelixis, Inc. | P70S6 kinase modulators and method of use |
| US20050137187A1 (en) | 2003-12-23 | 2005-06-23 | Souers Andrew J. | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| US7049307B2 (en) | 2003-12-23 | 2006-05-23 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| US20050137243A1 (en) | 2003-12-23 | 2005-06-23 | Souers Andrew J. | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| US7071182B2 (en) | 2003-12-23 | 2006-07-04 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| CN1922174A (zh) | 2004-02-20 | 2007-02-28 | 贝林格尔·英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
| RU2006134005A (ru) | 2004-02-27 | 2008-04-10 | Шеринг Корпорейшн (US) | Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с |
| EP1725544B1 (en) | 2004-03-09 | 2009-05-27 | Boehringer Ingelheim Pharmaceuticals Inc. | 3-[4-heterocyclyl-1,2,3-triazol-1-yl]-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases |
| WO2005099824A1 (en) | 2004-03-30 | 2005-10-27 | Synta Pharmaceuticals, Corp. | 1-glyoxylamide indolizines for treating lung and ovarian cancer |
| JPWO2005102381A1 (ja) | 2004-04-26 | 2008-03-06 | 小野薬品工業株式会社 | カテプシンk阻害薬およびpth類を併用することを特徴とする骨密度増加剤 |
| ES2725457T3 (es) | 2004-09-14 | 2019-09-24 | Gilead Pharmasset Llc | Preparación de ribofuranosil pirimidinas y purinas 2'fluoro-2'-alquil-sustituidas u otras opcionalmente sustituidas y sus derivados |
| CN101437524B (zh) * | 2004-09-14 | 2012-01-11 | 法莫赛特股份有限公司 | 2'-氟-2'-烷基-取代的或其它任选取代的呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| US7531560B2 (en) | 2004-11-10 | 2009-05-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-cytokine heterocyclic compounds |
| GB0426661D0 (en) | 2004-12-06 | 2005-01-05 | Isis Innovation | Pyrrolidine compounds |
| US20090048285A1 (en) | 2005-01-19 | 2009-02-19 | Benjamin Pelcman | Pyrrolopyridines Useful in the Treatment of Inflammation |
| GB0503054D0 (en) | 2005-02-14 | 2005-03-23 | Smithkline Beecham Corp | Chemical compounds |
| WO2006091862A2 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Cytokine inhibitors and their use in therapy |
| US20080214527A1 (en) | 2005-08-04 | 2008-09-04 | Takashi Kawasuji | Hiv Integrase Inhibitors |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
| TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯 |
| PL1940786T3 (pl) | 2005-09-16 | 2010-12-31 | Arrow Therapeutics Ltd | Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| CN101007798B (zh) | 2006-01-24 | 2011-01-26 | 中国人民解放军军事医学科学院毒物药物研究所 | 苯并间二氧杂环戊烯衍生物及其制备方法和医药用途 |
| WO2008091349A1 (en) | 2006-02-14 | 2008-07-31 | The President And Fellows Of Harvard College | Bifunctional histone deacetylase inhibitors |
| US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
| TW200815437A (en) | 2006-06-13 | 2008-04-01 | Bayer Schering Pharma Ag | Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| TW200815438A (en) | 2006-06-13 | 2008-04-01 | Bayer Schering Pharma Ag | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| EP1867647A1 (en) | 2006-06-13 | 2007-12-19 | Bayer Schering Pharma Aktiengesellschaft | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. |
| EP1867648A1 (en) | 2006-06-13 | 2007-12-19 | Bayer Schering Pharma Aktiengesellschaft | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. |
| KR101130380B1 (ko) | 2006-06-13 | 2012-04-23 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도 |
| EP1870410A1 (en) | 2006-06-13 | 2007-12-26 | Bayer Schering Pharma Aktiengesellschaft | Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| US8158810B2 (en) | 2006-07-27 | 2012-04-17 | Gilead Sciences, Inc. | ALDH-2 inhibitors in the treatment of addiction |
| EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| EP1932845A1 (en) | 2006-12-15 | 2008-06-18 | Bayer Schering Pharma Aktiengesellschaft | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| US20090062273A1 (en) | 2006-12-15 | 2009-03-05 | Ingo Hartung | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. |
| WO2008091681A2 (en) | 2007-01-23 | 2008-07-31 | Housey Gerard M | Theramutein modulators |
| EP2134689B1 (en) | 2007-03-16 | 2014-04-23 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| EP2142550A1 (en) | 2007-04-02 | 2010-01-13 | Palau Pharma, S.A. | Pyrrolopyrimidine derivatives as jak3 inhibitors |
| WO2008124848A1 (en) | 2007-04-10 | 2008-10-16 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| EP2170888B1 (en) | 2007-06-29 | 2015-04-22 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| AU2008279447A1 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| EP2188272B1 (en) | 2007-08-06 | 2016-02-24 | reMynd NV | Phenyl- and benzylthiazolylpiperazine derivatives for the treatment of neurodegenerative diseases |
| WO2009034433A2 (en) | 2007-09-10 | 2009-03-19 | Glenmark Pharmaceuticals, S.A. | 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands |
| CN101861151B (zh) | 2007-09-14 | 2014-08-13 | 梅特希尔基因公司 | 使用组蛋白脱乙酰基酶hdac1、hdac2和/或hdac3的选择性抑制剂和微管稳定剂的癌症组合治疗 |
| CA2703163A1 (en) | 2007-10-22 | 2009-04-30 | Memory Pharmaceuticals Corporation | (1,4-diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone ligands for nicotinic acetylcholine receptors, useful for the treatment of disease |
| RS53602B1 (sr) | 2007-11-29 | 2015-02-27 | Boehringer Ingelheim International Gmbh | DERIVATI AMIDA 6,7-DIHIDRO-5H-IMIDAZO[1,2-α]IMIDAZOL-3-KARBOKSILNE KISELINE |
| EP2070929A1 (en) | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| RU2544856C2 (ru) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| WO2009105782A1 (en) | 2008-02-21 | 2009-08-27 | Sequoia Pharmaceuticals, Inc. | Hiv protease inhibitor and cytochrome p450 inhibitor combinations |
| AU2009233711B2 (en) | 2008-04-09 | 2015-02-12 | Infinity Pharmaceuticals, Inc | Inhibitors of fatty acid amide hydrolase |
| WO2009133834A1 (ja) | 2008-04-28 | 2009-11-05 | 塩野義製薬株式会社 | 血管内皮リパーゼ阻害活性を有するケトアミド誘導体 |
| US20090298834A1 (en) | 2008-06-02 | 2009-12-03 | Hassan Pajouhesh | 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers |
| US20090326019A1 (en) | 2008-06-11 | 2009-12-31 | Yat Sun Or | 3,4-bicyclic pyrrolidine antivirals |
| BRPI0914891A2 (pt) | 2008-06-20 | 2015-11-24 | Metabolex Inc | agonistas de aril gpr119 e usos dos mesmos |
| CA3012229C (en) | 2008-07-08 | 2020-11-10 | Incyte Holdings Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| FR2934593B1 (fr) | 2008-07-29 | 2010-09-10 | Pf Medicament | Derives dimeriques d'artemisinine et application en therapie anticancereuse |
| CA2732437C (en) | 2008-08-01 | 2017-11-21 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
| CN102159077A (zh) | 2008-08-21 | 2011-08-17 | 吉瑞工厂 | 用于治疗神经性疼痛的方法 |
| WO2010029299A1 (en) | 2008-09-12 | 2010-03-18 | Biolipox Ab | Pyrimidinone derivaties for use as medicaments |
| AR073397A1 (es) | 2008-09-23 | 2010-11-03 | Palau Pharma Sa | Derivados de (r) -3- (n,n-dimetilamino) pirrolidina |
| AU2009305669A1 (en) | 2008-10-16 | 2010-04-22 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| WO2010053998A1 (en) | 2008-11-05 | 2010-05-14 | Xenon Pharmaceuticals, Inc. | Spiro-condensed indole derivatives as sodium channel inhibitors |
| UY32306A (es) | 2008-12-09 | 2010-07-30 | Gilead Sciences Inc | Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos |
| WO2010068287A2 (en) | 2008-12-11 | 2010-06-17 | Angion Biomedica Corp. | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
| TW201035102A (en) | 2009-03-04 | 2010-10-01 | Gruenethal Gmbh | Sulfonylated tetrahydroazolopyrazines and their use as medicinal products |
| US8329907B2 (en) | 2009-04-02 | 2012-12-11 | Merck Patent Gmbh | Autotaxin inhibitors |
| AU2010234087B2 (en) | 2009-04-02 | 2016-05-12 | Merck Patent Gmbh | Piperidine and piperazine derivatives as autotaxin inhibitors |
| JP5690823B2 (ja) | 2009-07-08 | 2015-03-25 | レオ ファーマ アクティーゼルスカブ | Jak受容体およびタンパク質チロシンキナーゼ阻害薬としての複素環化合物 |
| CN105669553A (zh) | 2009-08-18 | 2016-06-15 | 文蒂雷克斯药品公司 | 作为toll样受体调节剂的取代的苯并氮杂* |
| CN105669552A (zh) | 2009-08-18 | 2016-06-15 | 文蒂雷克斯药品公司 | 作为toll样受体调节剂的取代的苯并氮杂* |
| DK2480552T3 (en) | 2009-09-21 | 2017-02-20 | Gilead Sciences Inc | 2 'FLUOROUS-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT |
| WO2011048611A1 (en) | 2009-10-07 | 2011-04-28 | Torrent Pharmaceuticals Limited | Novel fused pyridazine derivatives |
| BR112012009329A2 (pt) | 2009-10-22 | 2016-06-07 | Gilead Sciences Inc | derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia) |
| JP2013516470A (ja) | 2010-01-07 | 2013-05-13 | ポリメディックス・インコーポレーテッド | 抗ヘパリン化合物 |
| WO2011087051A1 (ja) | 2010-01-14 | 2011-07-21 | 国立大学法人金沢大学 | S1p2受容体アンタゴニストを含む粥状動脈硬化治療薬 |
| WO2011106106A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| RU2576662C2 (ru) | 2010-03-18 | 2016-03-10 | Энститю Пастер Корея | Противоинфекционные соединения |
| EP2560635A4 (en) | 2010-04-23 | 2013-04-03 | Kineta Inc | ANTIVIRAL CONNECTIONS |
| EP2560656A4 (en) | 2010-04-23 | 2013-11-27 | Kineta Inc | ANTIVIRAL CONNECTIONS |
| AR081039A1 (es) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | Inhibidores biciclicos fusionados de quinasa |
| WO2011146401A1 (en) | 2010-05-17 | 2011-11-24 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| WO2011145669A1 (ja) | 2010-05-19 | 2011-11-24 | 大日本住友製薬株式会社 | アミド誘導体 |
| US8940725B2 (en) | 2010-05-31 | 2015-01-27 | Ono Pharmaceutical Co., Ltd. | Purinone derivative |
| WO2012016186A1 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Macrocyclic kinase inhibitors and uses thereof |
| CN103119030A (zh) | 2010-07-30 | 2013-05-22 | 兰贝克赛实验室有限公司 | 基质金属蛋白酶抑制剂 |
| WO2012020567A1 (en) | 2010-08-09 | 2012-02-16 | Raqualia Pharma Inc. | Acyl piperazine derivatives as ttx-s blockers |
| JP6039559B2 (ja) | 2010-09-02 | 2016-12-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Lpa受容体アンタゴニストとしてのピラゾロピリジノン誘導体 |
| US20140148459A1 (en) | 2010-09-24 | 2014-05-29 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
| WO2012050868A1 (en) | 2010-09-28 | 2012-04-19 | Georgia Tech Research Corporation | Histone deacetylase (hdac) inhibitors targeting prostate tumors and methods of making and using thereof |
| US20120082658A1 (en) | 2010-10-01 | 2012-04-05 | Ventirx Pharmaceuticals, Inc. | Methods for the Treatment of Allergic Diseases |
| KR101866893B1 (ko) | 2010-10-01 | 2018-06-14 | 벤티알엑스 파마슈티칼스 인코포레이티드 | Tlr 아고니스트의 치료적 용도 및 병용 요법 |
| US9273028B2 (en) | 2010-10-29 | 2016-03-01 | Biogen Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| AR084217A1 (es) | 2010-12-10 | 2013-05-02 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| TWI574687B (zh) | 2011-01-03 | 2017-03-21 | 古利斯股份有限公司 | 具有鋅結合部份之刺蝟拮抗劑 |
| DK2663555T3 (en) | 2011-01-12 | 2017-03-27 | Ventirx Pharmaceuticals Inc | SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS |
| MX346387B (es) | 2011-01-12 | 2017-03-02 | Ventirx Pharmaceuticals Inc | Benzoazepinas sustituidas como moduladores de receptores tipo toll. |
| US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
| WO2012112743A1 (en) | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman - spirocyclic piperidine amides as modulators of ion channels |
| US9295754B2 (en) | 2011-02-24 | 2016-03-29 | Emory University | Noggin inhibitory compositions for ossification and methods related thereto |
| WO2012123938A1 (en) | 2011-03-17 | 2012-09-20 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Quinolone analogs for treating autoimmune diseases |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| ES2691745T3 (es) | 2011-04-08 | 2018-11-28 | Janssen Sciences Ireland Uc | Derivados de pirimidina para el tratamiento de infecciones víricas |
| DK2709619T3 (en) | 2011-05-16 | 2018-01-15 | Cellceutix Corp | RELATIONSHIPS FOR USING THE TREATMENT OF MUCOSITIS |
| JP6130827B2 (ja) | 2011-05-17 | 2017-05-17 | 塩野義製薬株式会社 | ヘテロ環化合物 |
| PL2709989T3 (pl) | 2011-05-18 | 2018-06-29 | Janssen Sciences Ireland Uc | Pochodne chinazoliny do leczenia infekcji wirusowych i dalszych chorób |
| EP3199537B1 (en) | 2011-05-19 | 2018-10-17 | Gilead Sciences, Inc. | Processes and intermediates for preparing anti-hiv agents |
| CA2833507A1 (en) | 2011-06-07 | 2012-12-13 | Dainippon Sumitomo Pharma Co., Ltd. | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof |
| WO2013006394A1 (en) | 2011-07-01 | 2013-01-10 | Institute For Hepatitis And Virus Research | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
| TWI454466B (zh) | 2011-07-22 | 2014-10-01 | 汪根欉 | 可用於有機薄膜太陽能電池之化合物及有機薄膜太陽能電池 |
| JP6100258B2 (ja) | 2011-07-29 | 2017-03-22 | メルク パテント ゲーエムベーハー | 電子素子のための化合物 |
| WO2013042139A1 (en) | 2011-09-23 | 2013-03-28 | Advinus Therapeutics Limited | Amide compounds, compositions and applications thereof |
| EP2768517A4 (en) | 2011-10-17 | 2015-03-11 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| BR112014012727B1 (pt) | 2011-11-29 | 2022-10-25 | Ono Pharmaceutical Co., Ltd | Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica |
| CA2857964A1 (en) | 2011-12-05 | 2013-06-13 | Brandeis University | Treatment of amyloidosis by compounds that regulate retromer stabilization |
| DE102011121022A1 (de) | 2011-12-13 | 2013-06-13 | Merck Patent Gmbh | Organische Sensibilisatoren für Up- Conversion |
| EP2794565B1 (en) | 2011-12-21 | 2017-07-26 | Novira Therapeutics Inc. | Hepatitis b antiviral agents |
| TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| EA039373B1 (ru) | 2012-02-08 | 2022-01-19 | Янссен Сайенсиз Айрлэнд Юси | Производные пиперидино-пиримидина для лечения вирусных инфекций |
| WO2013144228A1 (en) | 2012-03-29 | 2013-10-03 | Basf Se | Pesticidal methods using heterocyclic compounds and derivatives for combating animal pests |
| US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| MX2014011749A (es) | 2012-03-31 | 2015-01-22 | Hoffmann La Roche | 4-metil-dihidropirimidinas novedosas para el tratamiento y la prolifaxis de la infeccion por el virus de la hepatitis b. |
| JPWO2013161871A1 (ja) | 2012-04-25 | 2015-12-24 | 興和株式会社 | Tlr阻害作用を有するチオフェン誘導体 |
| SI2859009T1 (sl) | 2012-06-08 | 2017-12-29 | Gilead Sciences, Inc. | Makrociklični inhibitorji flaviviridae virusov |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| IN2014MN02652A (cg-RX-API-DMAC7.html) | 2012-06-08 | 2015-08-21 | Gilead Sciences Inc | |
| JP6302906B2 (ja) | 2012-08-10 | 2018-03-28 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染および他の疾患を治療するためのアルキルピリミジン誘導体 |
| WO2014031872A2 (en) | 2012-08-23 | 2014-02-27 | The Broad Institute, Inc. | Small molecule inhibitors for treating parasitic infections |
| CA2881057C (en) | 2012-08-28 | 2020-10-27 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| NZ704758A (en) | 2012-08-28 | 2018-06-29 | Janssen Sciences Ireland Uc | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| EP2892899B1 (en) | 2012-09-06 | 2018-03-21 | Bristol-Myers Squibb Company | Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
| CA2881322A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| WO2014045305A1 (en) | 2012-09-21 | 2014-03-27 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| ES2654143T3 (es) | 2012-10-02 | 2018-02-12 | Gilead Sciences, Inc. | Inhibidores de desmetilasas de histonas |
| MX386924B (es) | 2012-10-10 | 2025-03-19 | Janssen Sciences Ireland Uc | Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades. |
| US9663474B2 (en) | 2012-11-16 | 2017-05-30 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections |
| CN104918612B (zh) | 2012-12-06 | 2019-10-25 | 巴鲁克斯布隆伯格研究所 | 作为抗hbv感染的抗病毒剂的官能化苯甲酰胺衍生物 |
| US8987461B2 (en) | 2012-12-06 | 2015-03-24 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| JP2014133739A (ja) | 2012-12-12 | 2014-07-24 | Dainippon Sumitomo Pharma Co Ltd | インダゾール誘導体またはピロロピリジン誘導体からなる医薬 |
| SI2934145T1 (en) | 2012-12-19 | 2018-03-30 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CA2895808A1 (en) | 2012-12-21 | 2014-06-26 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| JP2016507496A (ja) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. | ブロモドメイン阻害剤としての新規複素環式化合物 |
| AP2015008502A0 (en) | 2012-12-24 | 2015-06-30 | Cadila Healthcare Ltd | Novel quinolone derivatives |
| HK1217649A1 (zh) | 2012-12-27 | 2017-01-20 | 德雷克塞尔大学 | 針對hbv感染的新型抗病毒劑 |
| CN105101970B (zh) | 2013-01-10 | 2018-11-20 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
| HUE033962T2 (en) | 2013-01-29 | 2018-01-29 | Redx Pharma Plc | Pyridine derivatives as soft rock (RHO kinase) inhibitors |
| GB201303109D0 (en) | 2013-02-21 | 2013-04-10 | Domainex Ltd | Novel pyrimidine compounds |
| KR102300861B1 (ko) | 2013-02-21 | 2021-09-10 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체 |
| SG10201707027SA (en) | 2013-02-27 | 2017-09-28 | Epitherapeutics Aps | Inhibitors of histone demethylases |
| JP6466348B2 (ja) | 2013-02-28 | 2019-02-06 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用 |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| JP6320506B2 (ja) | 2013-03-12 | 2018-05-09 | セルジーン クオンティセル リサーチ,インク. | ヒストンデメチラーゼ阻害剤 |
| RU2015143517A (ru) | 2013-03-13 | 2017-04-19 | Дженентек, Инк. | Пиразолсодержащие соединения и их применения |
| CA2903081A1 (en) | 2013-03-14 | 2014-09-25 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| WO2014151958A1 (en) | 2013-03-14 | 2014-09-25 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| ES2644828T3 (es) | 2013-03-15 | 2017-11-30 | Quanticel Pharmaceuticals Inc | Inhibidores de histona desmetilasa |
| HUE033542T2 (en) | 2013-04-03 | 2017-12-28 | Janssen Sciences Ireland Uc | Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B |
| WO2014179144A1 (en) | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
| TW202126620A (zh) | 2013-05-17 | 2021-07-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療b型肝炎藥物的用途 |
| PE20151951A1 (es) | 2013-05-17 | 2015-12-26 | Hoffmann La Roche | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b |
| HUE040446T2 (hu) | 2013-05-17 | 2019-03-28 | Janssen Sciences Ireland Uc | Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére |
| WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| EP3016953A4 (en) | 2013-07-02 | 2017-03-01 | Pharmacyclics, LLC | Purinone compounds as kinase inhibitors |
| WO2015011281A1 (en) * | 2013-07-25 | 2015-01-29 | Janssen R&D Ireland | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| JP2016530273A (ja) | 2013-08-20 | 2016-09-29 | シティ・オブ・ホープCity of Hope | 癌を治療するためのhdac8阻害剤 |
| KR101715090B1 (ko) | 2013-08-28 | 2017-03-13 | 한국화학연구원 | 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물 |
| US9920073B2 (en) | 2013-10-04 | 2018-03-20 | Drexel University | Compositions useful for inhibiting HIV-1 infection and methods using same |
| US10220034B2 (en) | 2013-10-18 | 2019-03-05 | Indiana University Research And Technology Corporation | Hepatitis B viral assembly effectors |
| AU2014337044A1 (en) | 2013-10-18 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| MX368158B (es) | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| CA2928003A1 (en) | 2013-11-14 | 2015-05-21 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis b infections |
| WO2015085238A1 (en) | 2013-12-05 | 2015-06-11 | The Regents Of The University Of California, A California Corporation | Inhibitors of lpxc |
| US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| PE20160686A1 (es) | 2014-01-30 | 2016-07-23 | Hoffmann La Roche | Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b |
| JP6553059B2 (ja) | 2014-02-05 | 2019-07-31 | ノヴィラ・セラピューティクス・インコーポレイテッド | Hbv感染の治療のための併用療法 |
| PL3102572T3 (pl) | 2014-02-06 | 2019-04-30 | Janssen Sciences Ireland Uc | Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B |
| US10533010B2 (en) | 2014-03-27 | 2020-01-14 | Vanderbilt University | Substituted indole Mcl-1 inhibitors |
| US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
| CN106459032B (zh) | 2014-05-13 | 2019-04-05 | 豪夫迈·罗氏有限公司 | 治疗和预防乙型肝炎病毒感染的新的二氢喹嗪酮类 |
| EP3150600B1 (en) | 2014-05-30 | 2018-06-27 | Qilu Pharmaceutical Co., Ltd. | Dihydropyrimido loop derivative as hbv inhibitor |
| WO2016008011A1 (en) | 2014-07-16 | 2016-01-21 | Novogen ltd | Functionalised and substituted indoles as anti-cancer agents |
| JP6506836B2 (ja) | 2014-08-14 | 2019-04-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | B型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン |
| CN112898308B (zh) | 2014-08-15 | 2026-08-07 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| JP2017526675A (ja) | 2014-08-27 | 2017-09-14 | ギリアード サイエンシーズ, インコーポレイテッド | ヒストンデメチラーゼを阻害するための化合物および方法 |
| EP3204379B1 (en) | 2014-10-10 | 2019-03-06 | Genentech, Inc. | Pyrrolidine amide compounds as histone demethylase inhibitors |
| US9637485B2 (en) | 2014-11-03 | 2017-05-02 | Hoffmann-La Roche Inc. | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection |
| US10435402B2 (en) | 2015-01-08 | 2019-10-08 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| JP6948952B2 (ja) | 2015-05-28 | 2021-10-13 | ビーエイエスエフ・ソシエタス・エウロパエアBasf Se | 均一系触媒によるカルボニル化合物の還元的アミノ化法 |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| WO2016201440A1 (en) | 2015-06-12 | 2016-12-15 | The Regents Of The University Of California | Spiroindolinones and therapeutic uses thereof |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| WO2017012379A1 (zh) | 2015-07-20 | 2017-01-26 | 中国科学院上海有机化学研究所 | 草酸酰胺类配体及其在铜催化芳基卤代物偶联反应中的用途 |
| WO2017015451A1 (en) | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| AR105911A1 (es) | 2015-09-03 | 2017-11-22 | Forma Therapeutics Inc | Inhibidores de hdac8 bicíclicos fusionados [6,6] |
| GB201516614D0 (en) | 2015-09-18 | 2015-11-04 | Redx Pharma Plc | Antibacterial compounds |
| KR102112192B1 (ko) | 2015-11-05 | 2020-05-19 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | Tlr7 효능제로서의 7-(티아졸-5-일)피롤로피리미딘 화합물 |
| CN113546052A (zh) | 2015-11-09 | 2021-10-26 | 吉利德科学公司 | 治疗人免疫缺陷病毒的治疗组合物 |
| US10662186B2 (en) | 2015-12-31 | 2020-05-26 | Shanghai Pharmaceuticals Holding Co., Ltd. | Substituted pyrimidines as cyclin-dependent kinase inhibitors |
| BR112018068177B1 (pt) * | 2016-03-09 | 2024-02-27 | Emory University | Composto, uso do composto e composição para eliminação do vírus da hepatite b com agentes antivirais |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| WO2017161524A1 (zh) | 2016-03-23 | 2017-09-28 | 华东理工大学 | 丙酮酸脱氢酶激酶抑制剂及其应用 |
| CN107226805A (zh) | 2016-03-24 | 2017-10-03 | 北京天诚医药科技有限公司 | 芳香族酰胺类衍生物、其制备方法及其在医药上的应用 |
| ES2946970T3 (es) | 2016-03-31 | 2023-07-28 | Vertex Pharma | Regulador de conductancia transmembrana de moduladores de fibrosis quística |
| TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| WO2017209265A1 (ja) | 2016-06-03 | 2017-12-07 | 塩野義製薬株式会社 | 二環性複素環誘導体およびそれらを含有する医薬組成物 |
| EP3468561A4 (en) | 2016-06-10 | 2019-12-04 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CN107537157B (zh) | 2016-06-29 | 2022-05-17 | 无敌媒体有限公司 | 用于减少具有虚拟货币的电子游戏中的欺诈的系统和方法 |
| JOP20190024A1 (ar) * | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ, インコーポレイテッド | Hbv複製阻害剤としての置換ピロリジン化合物 |
-
2017
- 2017-06-16 JO JOP/2019/0024A patent/JOP20190024A1/ar unknown
- 2017-08-24 UY UY0001037374A patent/UY37374A/es not_active Application Discontinuation
- 2017-08-25 SI SI201730822T patent/SI3504212T1/sl unknown
- 2017-08-25 MY MYPI2019000980A patent/MY192450A/en unknown
- 2017-08-25 EP EP17761755.2A patent/EP3504212B1/en active Active
- 2017-08-25 CN CN202110955764.6A patent/CN113620960A/zh active Pending
- 2017-08-25 SG SG11201901131VA patent/SG11201901131VA/en unknown
- 2017-08-25 KR KR1020197008165A patent/KR102224081B1/ko active Active
- 2017-08-25 CR CR20190100A patent/CR20190100A/es unknown
- 2017-08-25 ES ES17761755T patent/ES2879674T3/es active Active
- 2017-08-25 US US15/686,499 patent/US10328053B2/en active Active
- 2017-08-25 EP EP21173731.7A patent/EP3922634B1/en active Active
- 2017-08-25 CN CN201780059448.2A patent/CN109790168B/zh active Active
- 2017-08-25 PL PL17761755T patent/PL3504212T3/pl unknown
- 2017-08-25 JP JP2019510869A patent/JP6774562B2/ja active Active
- 2017-08-25 BR BR112019003415-3A patent/BR112019003415A2/pt not_active Application Discontinuation
- 2017-08-25 PE PE2019000413A patent/PE20190631A1/es unknown
- 2017-08-25 CA CA3033681A patent/CA3033681C/en active Active
- 2017-08-25 UA UAA201901737A patent/UA124673C2/uk unknown
- 2017-08-25 TW TW106128937A patent/TWI765906B/zh active
- 2017-08-25 PL PL21173731.7T patent/PL3922634T3/pl unknown
- 2017-08-25 NZ NZ750757A patent/NZ750757A/en unknown
- 2017-08-25 WO PCT/US2017/048565 patent/WO2018039531A1/en not_active Ceased
- 2017-08-25 ES ES21173731T patent/ES2967453T3/es active Active
- 2017-08-25 AU AU2017315863A patent/AU2017315863C1/en active Active
- 2017-08-25 PT PT177617552T patent/PT3504212T/pt unknown
- 2017-08-25 KR KR1020217006241A patent/KR102343747B1/ko active Active
- 2017-08-25 MX MX2019002049A patent/MX394010B/es unknown
-
2019
- 2019-02-12 IL IL264800A patent/IL264800B/en active IP Right Grant
- 2019-02-22 CO CONC2019/0001634A patent/CO2019001634A2/es unknown
- 2019-02-22 DO DO2019000040A patent/DOP2019000040A/es unknown
- 2019-02-22 CL CL2019000473A patent/CL2019000473A1/es unknown
- 2019-02-22 EC ECSENADI201912917A patent/ECSP19012917A/es unknown
- 2019-02-22 PH PH12019500393A patent/PH12019500393A1/en unknown
- 2019-02-25 SA SA519401180A patent/SA519401180B1/ar unknown
- 2019-03-07 ZA ZA2019/01431A patent/ZA201901431B/en unknown
- 2019-05-03 US US16/403,247 patent/US10874640B2/en active Active
- 2019-07-12 CL CL2019001976A patent/CL2019001976A1/es unknown
-
2020
- 2020-05-28 AU AU2020203499A patent/AU2020203499B2/en active Active
- 2020-10-02 JP JP2020167860A patent/JP6983296B2/ja active Active
- 2020-11-04 US US17/089,030 patent/US20210251957A1/en not_active Abandoned
-
2021
- 2021-02-09 IL IL280747A patent/IL280747B/en unknown
- 2021-06-10 DO DO2021000112A patent/DOP2021000112A/es unknown
- 2021-09-27 AU AU2021240103A patent/AU2021240103B2/en active Active
-
2022
- 2022-11-29 US US18/059,806 patent/US12161625B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6983296B2 (ja) | 置換ピロリジン化合物およびその使用 | |
| JP7050165B2 (ja) | Hbv複製阻害剤としての置換ピロリジン化合物 | |
| HK40064069B (en) | Substituted pyrrolizine compounds and uses thereof | |
| HK40064069A (en) | Substituted pyrrolizine compounds and uses thereof | |
| HK40009562B (en) | Substituted pyrrolizine compounds and uses thereof | |
| HK40009562A (en) | Substituted pyrrolizine compounds and uses thereof | |
| HK40032660B (en) | Substituted pyrrolizine compounds as hbv replication inhibitors | |
| HK40042757B (en) | Substituted pyrrolizine compounds as hbv replication inhibitors | |
| HK40042757A (en) | Substituted pyrrolizine compounds as hbv replication inhibitors | |
| EA038135B1 (ru) | Замещенные пирролизины и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190417 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190417 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200304 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200604 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200904 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201002 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6774562 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |